Photodynamic therapy (PDT), and sonodynamic therapy (SDT) that developed from PDT, have been studied for decades to treat solid tumors. Compared with other deep tumors, the accessibility of urological tumors (e.g., bladder tumor and prostate tumor) makes them more suitable for PDT/SDT that requires exogenous stimulation. Due to the introduction of nanobiotechnology, emerging photo/sonosensitizers modified with different functional components and improved physicochemical properties have many outstanding advantages in cancer treatment compared with traditional photo/sonosensitizers, such as alleviating hypoxia to improve quantum yield, passive/active tumor targeting to increase drug accumulation, and combination with other therapeutic modalities (e.g., chemotherapy, immunotherapy and targeted therapy) to achieve synergistic therapy. As WST11 (TOOKAD® soluble) is currently clinically approved for the treatment of prostate cancer, emerging photo/sonosensitizers have great potential for clinical translation, which requires multidisciplinary participation and extensive clinical trials. Herein, the latest research advances of newly developed photo/sonosensitizers for the treatment of urological cancers, and the efficacy, as well as potential biological effects, are highlighted. In addition, the clinical status of PDT/SDT for urological cancers is presented, and the optimization of the photo/sonosensitizer development procedure for clinical translation is discussed.

Aligned P(VDF-TrFE) nanofibers are successfully fabricated by advanced electrospinning. The aligned feature of the nanofibers is achieved by using parallel electrodes, which is fabricated by lithography and wet etching, and a rotating drum collector. Scanning electron microscope (SEM) images show that the nanofibers are highly ordered with a smooth surface and uniform diameter. X-ray diffraction (XRD) and Fourier Transform Infrared spectrum (FTIR) tests indicate that the fibers contain high β phase content. The nanogenerator based on aligned P(VDF-TrFE) nanofibers exhibits good electric performance with a maximum output voltage as high as 12 V and peak-peak short circuit current about 150 nA, highlighting the potential application of P(VDF-TrFE) on self-powered and wearable devices.

A piezoelectric nanogenerator based on poly(vinylidene fluoride trifluoroethylene) [P(VDF-TrFE)] nanofibers with an Au interdigital electrode (IDT)/P(VDF-TrFE) nanofiber film/well-ordered cylindrical cavity structure was prepared by combining Au IDTs with a rotary collector to obtain highly aligned P(VDF-TrFE) nanofiber arrays. The Au IDTs work not only as parallel electrodes to collect P(VDF-TrFE) nanofibers during electrospinning but also as charge-collecting electrodes in the nanogenerator. The well-ordered cylindrical cavities improve output performance by enhancing the deformation of P(VDF-TrFE) nanofiber films when subjected to external force. The nanogenerator performs well; as an example of application, we demonstrate energy harvesting from human walking, with a peak output voltage of 5 V and a peak short-circuit current of 1.2 μA. Such a device could have practical applications in wearable, self-powered devices.

A piezoelectric nanogenerator with self-amplified output is prepared with a polydimethylsiloxane (PDMS)/silver nanowire (Ag NW)/poly(vinylidene fluoride-trifluoroethylene) sandwich structure. The Ag NWs facilitate the collection of induced charge generated by the piezoelectric film, and the micro-patterned PDMS films multiply the devices sensitivity under external compression. The nanogenerator exhibits good performance, with a peak open circuit voltage of 1.2 V, and a peak short circuit current of 82 nA. These findings highlight the potential of the nanogenerator in self-powered devices and wearable energy harvesters.

Circulating tumor cells (CTCs) are a type of cancer cells that circulate in the peripheral blood after breaking away from solid tumors and are essential for the establishment of distant metastasis. Up to 90% of cancer-related deaths are caused by metastatic cancer. As a new type of liquid biopsy, detecting and analyzing CTCs will provide insightful information for cancer diagnosis, especially the in-time disease status, which would avoid some flaws and limitations of invasive tissue biopsy. However, due to the extremely low levels of CTCs among a large number of hematologic cells, choosing immunocapture platforms for CTC detection and isolation will achieve good performance with high purity, selectivity, and viability. These properties are directly associated with precise downstream analysis of CTC profiling. Recently, inspired by the nanoscale interactions of cells in the tissue microenvironment, platforms based on nanomaterials have been widely explored to efficiently enrich and sensitively detect CTCs. In this review, various immunocapture platforms based on different nanomaterials for efficient isolation and sensitive detection of CTCs are outlined and discussed. First, the design principles of immunoaffinity nanomaterials are introduced in detail. Second, the immunocapture and release of platforms based on nanomaterials ranging from nanoparticles, nanostructured substrates, and immunoaffinity microfluidic chips are summarized. Third, recent advances in single-cell release and analysis of CTCs are introduced. Finally, some perspectives and challenges are provided in future trends of CTC studies.